Inogen delivered another quarter of mid-single-digit revenue growth, reaching over $92 million, buoyed by robust domestic and international demand for portable oxygen concentrators (POCs) while also demonstrating progress toward profitability.

• Achieved 15% year-over-year unit growth in POCs, contributing to seven consecutive quarters of mid-single-digit revenue growth.
• International B2B sales surged 19% year-over-year, emphasizing the success of global market expansion efforts.
• Adjusted EBITDA reached $2.3 million, marking the third consecutive quarter of profitability, with revised full-year expectations now approximating $2 million.
• Launch of Voxi 5, a new stationary oxygen concentrator, is gaining traction, enhancing product offerings in the oxygen therapy market.
• Ongoing R&D investment and a focused strategy on international markets position Inogen for sustained growth in the underpenetrated COPD space.